Literature DB >> 2419427

Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links.

D W MacGlashan, S P Peters, J Warner, L M Lichtenstein.   

Abstract

Human basophils release approximately 90 pmol of LTC4/micrograms histamine when challenged with anti-IgE antibody, but donor to donor variation produces a 1000-fold range of response. There is little conversion to LTC4 to LTE4 in purified preparations of basophils, but conversion to LTE4 does occur if cell densities are high during incubation. Like histamine release, leukotriene release is calcium and temperature dependent and is complete in 20 min, with a t1/2 of approximately 8 min. The process of desensitization also ablates leukotriene release, but there is a distinct two phase process where leukotriene release is enhanced after 5 min of desensitization, whereas histamine release is inhibited and total ablation of leukotriene release occurs only after 45 min of desensitization. Human basophils respond well to stimulation with covalently cross-linked trimeric IgE myeloma but respond poorly to dimeric IgE. This differential sensitivity to the two forms of cross-linked IgE is most exaggerated in the context of leukotriene release, where dimer is 30-fold less efficacious and 100- to 1000-fold less potent than trimer on some donors' basophils. This dichotomy of response is also observed in antigen-challenged cells, where the bivalent hapten, BPO2, also poorly induces leukotriene release in accord with the fact that it predominantly induces dimeric cross-links of penicillin-specific IgE. Anti-IgE dose-response curves reveal a region of dimeric cross-link dominance that may explain the peculiar differences observed in pharmacologic studies of basophil release induced with antigen vs anti-IgE. In addition, there is a continuum of "releasability," where some donors' basophils display no response (histamine or leukotriene release) to dimeric IgE, and others' basophils are essentially equally responsive to both dimeric and trimeric IgE. This releasability difference manifests itself by conferring increased sensitivity to antigenic challenge in those donors' basophils capable of responding to dimeric cross-links such that these donors' basophils are capable of releasing histamine upon antigen challenge while possessing only 50 molecules of cell surface antigen-specific IgE; other dimer-insensitive donors' basophils require 6 to 10-fold greater IgE densities for equal histamine release.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419427

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  The release of leukotriene B4 from human skin in response to substance P: evidence for the functional heterogeneity of human skin mast cells among individuals.

Authors:  T Okabe; M Hide; O Koro; N Nimi; S Yamamoto
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Ionic regulation of human basophil releasability. I. Inhibitory effect of copper.

Authors:  A Tedeschi; M Arquati; M Lorini; N Milazzo; A Miadonna
Journal:  Agents Actions       Date:  1992-09

Review 3.  Clinical significance of anti-IgE autoantibodies and immune complexes containing IgE.

Authors:  C G Magnusson; S G Johansson
Journal:  Clin Rev Allergy       Date:  1989

Review 4.  IgE and FcepsilonRI regulation.

Authors:  Donald MacGlashan
Journal:  Clin Rev Allergy Immunol       Date:  2005-08       Impact factor: 8.667

Review 5.  Nonspecific histamine-releasing properties of general anesthetic drugs.

Authors:  G Marone; C Stellato; P Mastronardi; B Mazzarella
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

6.  Polymerization of actin does not regulate desensitization in human basophils.

Authors:  Donald MacGlashan; Natalia Vilariño
Journal:  J Leukoc Biol       Date:  2009-01-15       Impact factor: 4.962

Review 7.  Cross-linking reconsidered: binding and cross-linking fields and the cellular response.

Authors:  B Sulzer; R J De Boer; A S Perelson
Journal:  Biophys J       Date:  1996-03       Impact factor: 4.033

8.  Structure of the omalizumab Fab.

Authors:  Rasmus K Jensen; Melanie Plum; Luna Tjerrild; Thilo Jakob; Edzard Spillner; Gregers Rom Andersen
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-03-20       Impact factor: 1.056

9.  Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.

Authors:  Rui Zhu; Yanan Zheng; Wendy S Putnam; Jennifer Visich; Mark D Eisner; John G Matthews; Karin E Rosen; David Z D'Argenio
Journal:  AAPS J       Date:  2013-02-15       Impact factor: 4.009

10.  Syk expression in peripheral blood leukocytes, CD34+ progenitors, and CD34-derived basophils.

Authors:  Susan S Ishmael; Donald W MacGlashan
Journal:  J Leukoc Biol       Date:  2009-11-04       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.